.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
UBS
QuintilesIMS
Colorcon
Novartis
Express Scripts
Farmers Insurance
US Army
Cipla

Generated: September 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Use of mometasone furoate for treating airway passage and lung diseases
Abstract:The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
Inventor(s): Sequeira; Joel A. (Scotch Plains, NJ), Cuss; Francis M. (Basking Ridge, NJ), Nolop; Keith B. (Millburn, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Nagabhushan; Nagamani (Parsippany, NJ), Patrick; James E. (Belle Meade, NJ), Cayen; Mitchell (Bedminster, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/763,295
Patent Claims: 1. A method of treating a corticosteroid-responsive disease of the lower airway passages or of the lungs comprising administering once daily to said passages or lungs from a dry powder inhaler about 400 micrograms of mometasone furoate.

2. The method of claim 1, wherein the mometasone furoate is administered as anhydrous mometasone furoate.

3. The method of claim 1, wherein the mometasone furoate is administered as mometasone furoate monohydrate.

4. The method of claim 1, wherein the mometasone furoate is administered together with a bronchodilator.

5. The method of claim 1, wherein the disease is at least one member selected from asthma, chronic obstructive pulmonary disease, granulomatous diseases, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and bronchopulmonary dysplasia.

6. The method of claim 1, wherein there are administered 400 micrograms of mometasone furoate by two inhalations of about 200 micrograms of mometasone furoate.

7. The method of claim 6, wherein the disease comprises asthma.

8. The method of claim 1, wherein there are administered 400 micrograms of mometasone furoate by one inhalation of about 400 micrograms of mometasone furoate.

9. The method of claim 8, wherein the disease comprises asthma.

10. A method of treating a corticosteroid-responsive disease of the lower airway passages or of the lungs, comprising administering once daily to said passages or lungs from a dry powder inhaler about 800 micrograms of mometasone furoate.

11. The method of claim 10, wherein the mometasone furoate is administered as anhydrous mometasone furoate.

12. The method of claim 10, wherein the mometasone furoate is administered as mometasone furoate monohydrate.

13. The method of claim 10, wherein the disease is at least one member selected from asthma, chronic obstructive pulmonary disease, granulomatous diseases, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and bronchopulmonary dysplasia.

14. The method of claim 10, wherein there are administered 800 micrograms of mometasone furoate by two inhalations of about 400 micrograms of mometasone furoate.

15. The method of claim 14, wherein the disease comprises chronic obstructive pulmonary disease.

16. The method of claim 10, wherein there are administered 800 micrograms of mometasone furoate by four inhalations of about 200 micrograms of mometasone furoate.

17. The method of claim 16, wherein the disease comprises chronic obstructive pulmonary disease.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Covington
Harvard Business School
Novartis
McKesson
Accenture
Medtronic
Express Scripts
Colorcon
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot